Radek C Skoda

9PUBLICATIONS
35CO-AUTHORS
Haematological tumoursHaematologyAdolescent healthMolecular targetsMetabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 30, 2026
A single JAK2-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice.

|Nov 11, 2025
JAK2/JAK2V617F heterodimers activate STAT1 and AhR to promote thrombocytosis.

Radek C Skoda, Olli Silvennoinen

|Mar 13, 2025
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw

|Mar 12, 2025
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Marc Usart, Quentin Kimmerlin, Jan Stetka

|Mar 17, 2024
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

Marc Usart, Jan Stetka, Damien Luque Paz

|Jan 31, 2024
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

Marc Usart, Nils Hansen, Jan Stetka

Pageof 2

Frequent Collaborators

4 joint publications

Jan Stetka

3 joint publications

Quentin Kimmerlin

3 joint publications

Marc Usart

2 joint publications

Damien Luque Paz